Evidence map›Paper›PMID 41376297›Full record

ArticleAngewandte Chemie (International ed. in English)2026

Caylobolide B: Structure Revision, Total Synthesis, Biological Characterization, and Discovery of New Analogues.

Malcolm R P George, Lobna A Elsadek, Max Deering, Larissa Costa de Almeida, Jasper L Tyler, Adam Noble, Valerie J Paul, Hendrik Luesch, Craig P Butts, Varinder K Aggarwal

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Malcolm R P George *School of Chemistry, University of Bristol, Cantock's Close, Bristol, BS8 1TS, UK.
Lobna A Elsadek *Department of Medicinal Chemistry and Center for Natural Products, Drug Discovery and Development (CNPD3), University of Florida, PO Box 100485, Gainesville, FL 32610, USA.
Max DeeringSchool of Chemistry, University of Bristol, Cantock's Close, Bristol, BS8 1TS, UK.
Larissa Costa de AlmeidaDepartment of Medicinal Chemistry and Center for Natural Products, Drug Discovery and Development (CNPD3), University of Florida, PO Box 100485, Gainesville, FL 32610, USA.
Jasper L TylerSchool of Chemistry, University of Bristol, Cantock's Close, Bristol, BS8 1TS, UK.ORCID 0000-0002-3155-1847
Adam NobleSchool of Chemistry, University of Bristol, Cantock's Close, Bristol, BS8 1TS, UK.
Valerie J PaulSmithsonian Marine Station, 701 Seaway Drive, Fort Pierce, FL 34949, USA.
Hendrik LueschDepartment of Medicinal Chemistry and Center for Natural Products, Drug Discovery and Development (CNPD3), University of Florida, PO Box 100485, Gainesville, FL 32610, USA.
Craig P ButtsSchool of Chemistry, University of Bristol, Cantock's Close, Bristol, BS8 1TS, UK.
Varinder K AggarwalSchool of Chemistry, University of Bristol, Cantock's Close, Bristol, BS8 1TS, UK.ORCID 0000-0003-0344-6430

Funding

Integrative Multidisciplinary Discovery Platform to Unlock Marine Natural Products Therapeutic OpportunitiesRM1GM145426 · NIGMS · UNIVERSITY OF FLORIDA · PI Mohamed Abou Donia, Steven D Bruner · 2022 to 2026
$8.8M
Chemistry-Biology Interface Training Program at the University of FloridaT32GM136583 · NIGMS · UNIVERSITY OF FLORIDA · PI Chenglong Li · 2020 to 2026
$1.1M
NMR console upgrade for structural biology and metabolomicsS10OD028753 · OD · UNIVERSITY OF FLORIDA · PI LONG, JOANNA R · 2020 to 2020
$600k
Discovery and Mechanistic Characterization of New Cytotoxic Agents from Marine CyanobacteriaF31GM143915 · NIGMS · UNIVERSITY OF FLORIDA · PI ELSADEK, LOBNA · 2021 to 2022
$89k
Bristol Centre for Synthetic Biology (BB/L01386X/1)Bristol Centre for Synthetic Biology (BB/V019163/1)EPSRC EP/S024107/1NIGMS NIH HHS F31 GM143915NIGMS NIH HHS RM1 GM145426NIGMS NIH HHS T32 GM136583NIH HHS RM1GM145426NIH HHS S10 OD028753NIH HHS T32GM136583the University of Florida and F31GM143915
6 · The paper itself

Abstract

The unique potential of marine polyhydroxylated macrolides in chemical biology and drug discovery has long been constrained by their structural complexity and limited material availability, frustrating efforts in stereochemical assignment, synthesis, and mechanism-of-action elucidation. Here, we establish an integrated workflow, combining chemogenomic profiling, ultra-high-resolution NMR, and modular total synthesis, for the comprehensive functional and structural interrogation of this challenging natural product class. Applying this approach to caylobolides, natural products isolated from scarce samples of Okeania sp., we performed structure-activity relationship studies revealing that acetylation at C29 markedly reduces both cytotoxicity and antifungal activity, pinpointing a key pharmacophore. Mechanistic profiling suggests that these macrolides disrupt membrane integrity, similar to amantelide A. Using natural compound samples, we simultaneously revised the structure of caylobolide B through

Indexed as

Antifungal AgentsBiological ProductsMacrolidesDrug DiscoveryHumansMicrobial Sensitivity TestsMolecular StructureStructure-Activity RelationshipAntifungal AgentsBiological ProductsMacrolidesChemogenomic profilingMarine macrolidesNatural productsStructural elucidationTotal synthesis

Identifiers

PMID41376297
PMCPMC12828451

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.